Filing Flows › Starling Oncology (STLN) › Stock forecast & fair value
Starling Oncology (STLN) stock forecast and price target
Starling Oncology (STLN) trades at $3.62. 4 analysts' median price target is $9.50 (+162%), from $9.00 to $11.00.
Starling Oncology's latest quarter
Starling Oncology, Q3 2026: revenue $170M (+24% year over year), operating margin -1.8%, net loss $15.7M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for STLN stock?
The median of 4 analysts' 12-month targets is $9.50, +162% from $3.62; the range is $9.00 to $11.00. The average rating is strong buy.
Does Starling Oncology usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is STLN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.